STOCK TITAN

Lakefront creates 150K employee share subscription rights

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics NV (LKFT) says its board approved and created 150,000 subscription rights under a new plan on November 10, 2026, for compensation of current and potential employees of the company and its subsidiaries. Each right permits subscription to one new Lakefront share. Other employee plans have 14,197,983 subscription rights outstanding. Separately, one right issued to Gilead Therapeutics permits subscription for a maximum number of shares sufficient to bring Gilead and its affiliates’ holding to 29.9% of actually issued and outstanding shares after exercise.

Filing Explained

This 6-K and its release are incorporated by reference into Lakefront’s listed Form S-8 registration statements, while the rights are described as subscriptions to securities not yet issued.

New plan subscription rights 150,000 rights Created November 10, 2026, for compensation of current and potential employees.
Shares per subscription right 1 share Each right under the new plan permits subscription to one new Lakefront share.
Shares and voting rights 65,897,071 shares Total number of securities conferring voting rights; also the stated denominator.
Repurchased shares 1,985,157 shares Voting rights attached to these shares held by the company are suspended.
Other employee-plan subscription rights 14,197,983 rights Rights under other outstanding employee subscription right plans.
Gilead Therapeutics subscription rights 1 right The right permits subscription for a maximum number of shares sufficient to bring Gilead and affiliates to the stated ownership level after exercise.
Gilead ownership level 29.9% The level the Gilead right is intended to bring Gilead and its affiliates to after exercise.
Total share capital €356,444,938.61 Lakefront’s currently stated total share capital.
subscription rights financial
"150,000 subscription rights were created for compensation"
Subscription rights are short-term privileges given to existing shareholders to buy additional new shares before the general public, typically at a set price and in proportion to their current holdings. Think of it as getting a coupon for first dibs on extra slices of a pizza so your share of the pie doesn’t shrink; exercising them can be a cheaper way to maintain your ownership and voting power, while ignoring them can reduce your stake and potential future earnings.
authorized capital financial
"within the framework of the authorized capital"
Authorized capital is the maximum value or number of shares a company is legally allowed to issue as set in its founding documents. For investors, it signals how much the company can expand ownership or raise money without changing those documents, which affects the risk of ownership being diluted and the company’s flexibility to fund growth—think of it like the number of seats allowed on a bus before you must buy a new one.
denominator financial
"the “denominator”"
The denominator is the number on the bottom of a fraction that shows the total population or base used to calculate a rate, percentage or ratio — for example, the total shares outstanding when calculating earnings per share, or all trial participants when reporting a safety rate. It matters to investors because changing the denominator (by issuing more shares, changing the population measured, or narrowing the base) can make percentages and per‑unit figures look better or worse even if the underlying raw numbers stay the same, much like changing the size of a pizza makes each slice appear larger or smaller.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many subscription rights did LKFT create under its November 2026 plan?

LKFT created 150,000 subscription rights on November 10, 2026, for compensation of current and potential employees of the company and its subsidiaries.

How many shares can each LKFT subscription right buy?

Each right permits subscription to one new Lakefront share.

What is the Gilead Therapeutics subscription right for?

The separate right issued to Gilead Therapeutics permits subscription for a maximum number of shares sufficient to bring Gilead and its affiliates’ holding to 29.9% of actually issued and outstanding shares after exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).


On November 18, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated November 18, 2026


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: November 18, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Lakefront Creates New Subscription Right Plan

Mechelen, Belgium; November 18, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) announced that its Board of Directors has created 150,000 subscription rights under a new subscription right plan on November 10, 2026.

On November 10, 2026, the Board of Directors of Lakefront approved the “Subscription Right Plan November 2026”, intended for personnel of the Company and its subsidiaries, within the framework of the authorized capital. Under this subscription right plan, 150,000 subscription rights were created for compensation of current and potential future employees. Each subscription right gives the right to subscribe to one new Lakefront share. More information can be found in the Board report published on the Lakefront website at Special reports | Lakefront Biotherapeutics (https://lakefrontbio.com/investors/corporate-governance/special-reports/).

Lakefront’s total share capital currently amounts to €356,444,938.61; the total number of securities conferring voting rights is 65,897,071, which is also the total number of shares (the “denominator”). All securities conferring voting rights, all voting rights and all shares are of the same category. The voting rights attached to the repurchased shares held by the Company 1,985,157 are currently suspended.

In addition to the 150,000 subscription rights of Subscription Right Plan November 2026, the total number of rights to subscribe to not yet issued securities conferring voting rights is (i) 14,197,983 subscription rights under other outstanding employee subscription right plans, which equals 14,197,983 voting rights that may result from the exercise of those subscription rights, and (ii) one subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 29.9% of the actually issued and outstanding shares after the exercise of the subscription right. Lakefront does not have any convertible bonds or shares without voting rights outstanding.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s subscription rights under the Subscription Right Plan November 2026, including the rights to subscribe to not yet issued securities conferring voting rights. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Filing Exhibits & Attachments

1 document

Keep reading